Bioventus（BVS）株式概要
医療機器メーカーであるバイオベンタス社は、米国内外の疼痛緩和と筋骨格系治療に注力している。 詳細
BVS Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bioventus Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$12.98 |
| 52週高値 | US$15.89 |
| 52週安値 | US$6.26 |
| ベータ | 0.65 |
| 1ヶ月の変化 | -8.98% |
| 3ヶ月変化 | 50.93% |
| 1年変化 | 79.53% |
| 3年間の変化 | 325.57% |
| 5年間の変化 | -6.48% |
| IPOからの変化 | -32.43% |
最新ニュース
ナラティブ更新 • Sep 03
BVS: Fair Value View Will Rely On Steady Margins And P/E
Analysts now view Bioventus as fairly valued at about $15 per share, up from roughly $13, citing updated assumptions for revenue growth, profit margins, the discount rate, and future P/E that together support a higher long term price target. What’s in the News for Bioventus Bioventus has started a review of multiple strategic alternatives after receiving an unsolicited acquisition proposal and several additional expressions of interest, with Latham & Watkins LLP advising the company on the process.
ナラティブ更新 • Aug 20
BVS: Potential Sale Review And 2026 Outlook Will Support Further Upside
Analysts have increased their price target on Bioventus to $17.60 from $14.80, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E, which together support a higher valuation framework. What’s in the News for Bioventus Bioventus is reviewing multiple strategic alternatives after receiving an unsolicited acquisition proposal and additional expressions of interest, with Latham & Watkins LLP engaged as legal adviser.
ナラティブ更新 • Aug 06
BVS: Reaffirmed 2026 Sales Outlook Will Support A Higher Share Price
Analysts have raised their price target for Bioventus from $16.00 to $18.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E as key drivers of the change. What’s in the News for Bioventus Bioventus reaffirmed its earnings guidance for the twelve months ending December 31, 2026, maintaining the 2026 financial outlook that was first issued on May 6, 2026.Recent updates
ナラティブ更新 • Sep 03
BVS: Fair Value View Will Rely On Steady Margins And P/E
Analysts now view Bioventus as fairly valued at about $15 per share, up from roughly $13, citing updated assumptions for revenue growth, profit margins, the discount rate, and future P/E that together support a higher long term price target. What’s in the News for Bioventus Bioventus has started a review of multiple strategic alternatives after receiving an unsolicited acquisition proposal and several additional expressions of interest, with Latham & Watkins LLP advising the company on the process.ナラティブ更新 • Aug 20
BVS: Potential Sale Review And 2026 Outlook Will Support Further Upside
Analysts have increased their price target on Bioventus to $17.60 from $14.80, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E, which together support a higher valuation framework. What’s in the News for Bioventus Bioventus is reviewing multiple strategic alternatives after receiving an unsolicited acquisition proposal and additional expressions of interest, with Latham & Watkins LLP engaged as legal adviser.ナラティブ更新 • Aug 06
BVS: Reaffirmed 2026 Sales Outlook Will Support A Higher Share Price
Analysts have raised their price target for Bioventus from $16.00 to $18.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E as key drivers of the change. What’s in the News for Bioventus Bioventus reaffirmed its earnings guidance for the twelve months ending December 31, 2026, maintaining the 2026 financial outlook that was first issued on May 6, 2026.Seeking Alpha • Jul 07
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)
Summary Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments. The 2027 Hospital Outpatient Prospective Payment System and ASC proposed rule are key catalysts for BVS's recent stock surge. Read the full article on Seeking Alphaナラティブ更新 • Jun 17
BVS: 2026 Sales Guidance Will Support A Higher Share Price
Analysts maintained their $16.00 price target on Bioventus, noting only minor adjustments to assumptions such as the discount rate, revenue growth outlook, profit margin, and future P/E, which were not significant enough to change their overall valuation view. What's in the News for Bioventus Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, indicating expected net sales in the range of $600 million to $610 million.ナラティブ更新 • Jun 03
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have maintained their $14.80 price target for Bioventus, citing slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the updated view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million, based on company guidance.ナラティブ更新 • May 19
BVS: Index Inclusion And 2026 Guidance Will Support A Higher Price
Analysts have raised their Bioventus price target from $15.00 to $16.00, citing updated assumptions related to revenue growth, profit margins, discount rates, and future P/E levels. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million and implied growth of about 6% to 7% (company guidance).分析記事 • May 14
Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are
Investors were underwhelmed by the solid earnings posted by Bioventus Inc. ( NASDAQ:BVS ) recently. Our analysis says...ナラティブ更新 • May 01
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have maintained their Bioventus fair value estimate at $14.80 while making only small adjustments to key inputs such as the discount rate and expected future P/E, indicating fine-tuning of their valuation framework rather than a major change in outlook. What's in the News Bioventus Inc.ナラティブ更新 • Apr 17
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have modestly fine tuned their $14.80 price target for Bioventus, keeping it steady overall as minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions leave the valuation view essentially unchanged. What's in the News Bioventus Inc.ナラティブ更新 • Apr 03
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have revised their price target for Bioventus slightly lower from $15.00 to $14.80, reflecting updated fair value and discount rate assumptions while maintaining similar views on revenue growth, profit margin and future P/E expectations. What's in the News Bioventus Inc.ナラティブ更新 • Mar 19
BVS: 2026 Net Sales Guidance And Margin Outlook Will Support Further Upside
Analysts have adjusted their price target on Bioventus to $15.00 from $14.50, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that collectively support a slightly higher valuation. What's in the News Bioventus issued earnings guidance for 2026, setting expected net sales in a range of $600 million to $610 million.ナラティブ更新 • Mar 05
BVS: Refined Assumptions And 2026 Outlook Will Support Further Upside Potential
Analysts have adjusted their price target on Bioventus slightly lower from $15.00 to $14.50, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News Bioventus issued earnings guidance for 2026, with expected net sales of $600 million to $610 million.ナラティブ更新 • Feb 19
BVS: Higher Revenue Outlook And Richer Future P/E Will Drive Upside
Analysts have revised their Bioventus price target to $13.00 from $7.00, reflecting updated views on fair value, discount rate assumptions, revenue growth expectations, profit margin outlook and future P/E multiples. Valuation Changes Fair Value: revised to $13.00 from $7.00, indicating a higher assessed equity value per share.ナラティブ更新 • Feb 05
BVS: Fine Tuned Assumptions Will Support Further Upside Potential
Analysts have nudged their price target on Bioventus to US$15.00, a modest change that reflects fine tuning to inputs such as the discount rate, long term revenue growth, profit margin assumptions, and expected future P/E rather than a shift in their overall view of the company. Valuation Changes Fair Value: Maintained at US$15.00 per share, with no change in the overall valuation output.ナラティブ更新 • Jan 22
BVS: Reaffirmed 2025 Guidance And Stable Assumptions Will Support Further Upside
Analysts have kept their fair value estimate for Bioventus unchanged at US$15.00, with only slight tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This signals a broadly steady view of the stock's risk and return profile.ナラティブ更新 • Jan 07
BVS: Reaffirmed 2025 Guidance Will Support Ongoing Upside Potential
Analysts have kept their fair value estimate for Bioventus steady at US$15.00, citing only very small tweaks to inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions that do not materially change their overall view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2025, signaling no change to its previously communicated outlook.ナラティブ更新 • Dec 20
BVS: Reaffirmed 2025 Earnings Guidance Will Support Continued Upside Potential
Analysts have nudged their price target on Bioventus slightly higher to reflect modestly stronger revenue growth expectations and a marginally lower discount rate, while keeping fair value unchanged at approximately $15.00 per share. What's in the News Bioventus reaffirmed its full year 2025 earnings guidance, signaling management confidence in the current strategic and operating plan (company guidance).ナラティブ更新 • Dec 06
BVS: Earnings Guidance Will Support Continued Upside Potential In Shares
Analysts have modestly raised their price target on Bioventus to approximately $15.00 per share from about $15.00 per share, reflecting slightly lower perceived risk, stable long term growth expectations, and marginally improved profitability and valuation assumptions. What's in the News Bioventus reaffirmed its 2025 earnings guidance, projecting net sales between $560 million and $570 million.分析記事 • Nov 26
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...ナラティブ更新 • Nov 22
BVS: Earnings Guidance Is Expected To Drive Share Price Higher
Analysts have updated their price target for Bioventus, raising it modestly from $14.67 to $15.00 per share. This change reflects improved revenue growth expectations, despite a slightly higher discount rate and lower projected profit margin.ナラティブ更新 • Nov 03
BVS: Net Sales Guidance Will Sustain Bullish Outlook Into 2025
Analysts have slightly raised their price target for Bioventus to $14.67 per share, citing minor updates to the company's discount rate and future price-to-earnings assumptions. What's in the News Bioventus Inc.ナラティブ更新 • Oct 20
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have modestly raised their price target for Bioventus, increasing it by $0.00 to $14.67. They cited slight adjustments to their discount rate and future price-to-earnings assumptions.ナラティブ更新 • Oct 05
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have raised their price target for Bioventus from $12.75 to approximately $14.67 per share, citing improvements in projected revenue growth and a more favorable future price-to-earnings outlook. What's in the News Bioventus issued new earnings guidance for 2025 and estimates net sales between $560 million and $570 million.分析記事 • Aug 14
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative
NasdaqGS:BVS 1 Year Share Price vs Fair Value Explore Bioventus's Fair Values from the Community and select yours...分析記事 • Aug 09
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 in...新しいナラティブ • May 30
Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets
Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.分析記事 • May 07
Is Bioventus (NASDAQ:BVS) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Mar 08
Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues
Bioventus Inc.'s ( NASDAQ:BVS ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy right now...Seeking Alpha • Jan 05
Bioventus: Amply Rewarded For Recent Progress
Summary The stock of medical device concern Bioventus has roughly doubled over the past year, but has lost momentum recently. Management has done a commendable job in recent years in reducing debt and leverage ratios, and profits have rebounded significantly. What's ahead for Bioventus in 2025? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 12
Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
Summary Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE and EXOGEN. Despite positive performance, high debt and tough competition could impact future profits and valuation. Read the full article on Seeking Alpha株主還元
| BVS | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -7.7% | -5.5% | -0.9% |
| 1Y | 79.5% | -19.0% | 14.2% |
業界別リターン: BVS過去 1 年間で-19 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: BVS過去 1 年間で14.2 % の収益を上げたUS市場を上回りました。
価格変動
| BVS volatility | |
|---|---|
| BVS Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: BVS 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BVSの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2011 | 950 | Rob Claypoole | www.bioventus.com |
医療機器メーカーであるバイオベンタス社は、米国内外の疼痛緩和と筋骨格系治療に注力している。同社の製品ポートフォリオには、様々な関節内注射やヒアルロン酸注射からなる疼痛治療薬、変形性膝関節症治療用のデュロレーン、ジェルシン-3、SUPARTZなどの末梢神経刺激製品、慢性末梢痛治療用のスティムルーター、ターゲットとなる末梢神経に刺激を与えるタリスマンなどがあり、また、10分間のシングルスピン・サイクルで全血を処理して高収率のPRPを生成する卓上型装置であるXCELL PRPシステムもある。また、退行性脊椎疾患や脊椎変形症患者に対する精密骨切除術や、脳腫瘍や肝臓などの臓器の病変に対応する精密超音波神経・一般外科手術、最適な骨癒合を促進する各種製品を含む骨移植代替物も提供している。さらに、超音波手術システムneXus、硬組織の正確な切断を可能にする手術ソリューションBoneScalpel、可視化しながら骨除去ができるBoneScalpel Access、軟組織の正確な切除と除去ができるSonaStarシステム、SonaStar Eliteハンドピースとアクセサリーを提供している；超音波洗浄・剥離システム「ソニックワン」、整形外科、神経外科、再建骨移植術用の同種移植由来骨移植片「オステオアンプ」、骨移植片「シグナフューズ」、天然骨伝導性足場「ピュアボーン」、脱灰骨マトリックス「レフィシオ」。同社の修復療法には、低侵襲骨折治療やリハビリテーション製品が含まれる。同社製品には超音波骨刺激システム「Exogen」も含まれる。同社は医療機関、医師、患者、流通業者、ディーラーに製品を販売している。バイオベンタス社は2011年に設立され、ノースカロライナ州ダーラムに本社を置いている。
Bioventus Inc. 基礎のまとめ
| BVS 基礎統計学 | |
|---|---|
| 時価総額 | US$1.09b |
| 収益（TTM） | US$54.46m |
| 売上高(TTM) | US$581.85m |
16.3x
PER（株価収益率1.5x
P/SレシオBVS は割高か？
公正価値と評価分析を参照収益と収入
| BVS 損益計算書（TTM） | |
|---|---|
| 収益 | US$581.85m |
| 売上原価 | US$182.40m |
| 売上総利益 | US$399.45m |
| その他の費用 | US$344.98m |
| 収益 | US$54.46m |
直近の収益報告
Jun 27, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 0.80 |
| グロス・マージン | 68.65% |
| 純利益率 | 9.36% |
| 有利子負債／自己資本比率 | 89.6% |
BVS の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/13 17:14 |
| 終値 | 2026/09/11 00:00 |
| 収益 | 2026/06/27 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Bioventus Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Kyle Rose | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |